56 results about "Granuloma" patented technology

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The application relates to a method for identifying granulomatous mastitis and non-mass-like enhancement breast cancer, which comprises the following steps: reading original data of a peak enhancement period of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) collected by a magnetic resonance device, segmenting and labeling a lesion area to obtain a segmentation mask; pre-processing the DCE-MRI image and generating three-slice samples, including spatial resampling, intensity normalization, lesion centering and cutting, continuous three-slice sampling and mask superposition fusion; dividing the data into a training set and a test set according to the patient level, and adopting stratified sampling to maintain category balance; constructing a double-attention classification model based on DenseNet121, integrating a convolution block attention module (CBAM) and a selective kernel network module (SKNet) by adopting a progressive insertion strategy; training the model and testing by adopting a lesion-level voting strategy to obtain the identification result of the granulomatous mastitis and the non-mass-like enhancement breast cancer. The method solves the problem that the deep learning research on the identification of GM and NMEBC on the DCE-MRI is insufficient, and has high classification precision and good calibration.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The application discloses a kind of treatment granulomatous lobular mastitis plaster and preparation method thereof, it is related to traditional Chinese medicine technical field, and its technical solution points are: rhubarb, golden poplar, radix scutellariae, sanguisorba officinalis, gardenia, turmeric, purple grass, water decoct 2 times, first time 9-11 times water amount of medicinal materials is added, decoct 1-3 hours, second time 6-9 times water amount of medicinal materials is added, decoct 1-2 hours, two water decocting liquids are combined, after filtration, concentrate and obtain ointment, carry out coating, cut according to specification and place to make it solidification and shape.The application can realize the treatment granulomatous lobular mastitis, can reduce mastitis inflammation index score and inflammatory cell infiltration degree, by reducing the expression of IL6, CD86, TYROBP, ITGAX and regulating related path, play the role of treatment granulomatous lobular mastitis.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof. In some embodiments, an outcome of the methods of the present technology is increased relative to the same method comprising use of a corticosteroid.

This disclosure provides antibodies that specifically bind to human PAR-2, antigen-binding fragments thereof, and compositions comprising such antibodies or antigen-binding fragments thereof. [Solution] In certain embodiments, an antibody or antigen-binding fragment thereof that specifically binds to human PAR-2 ​​blocks the interaction between the PAR-2 ​​activating ligand and the extracellular domain of PAR-2, and / or blocks PAR-2 ​​activation by the PAR-2 ​​activating ligand. In further embodiments, the antibody or antigen-binding fragment can be used to treat diseases or conditions associated with increased PAR-2 ​​expression, and / or diseases or conditions that can be alleviated by antagonizing the activation of PAR-2 ​​by the PAR-2 ​​activating ligand (e.g., respiratory diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

The present disclosure relates to crystalline forms of N-(l-(tert-butyl)-lH-pyrazol-4-yl)-2-( 4-((6-((methylsulfonyl)quinolin-4-yl)oxy)-3-methylphenyl)acetamide of formula (II) and crystalline forms of salts thereof. The compound of formula (II) is a RIPK2 inhibitor for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and more specifically for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

The invention belongs to the field of animal models, particularly relates to a granulomatous mastitis animal model and a construction method thereof, and aims to solve the problems of low pathological matching degree and poor repeatability of an existing model. The construction method comprises the following steps: selecting an SPF-grade BALB / c female mouse (10 weeks old, 20-22 g), preparing human mammary gland fresh lesion tissue homogenate and lesion origin staphylococcus aureus liquid (1.4 * 10 < 8 >-1.5 * 10 < 8 > CFU / mL), mixing and emulsifying with a Freund's incomplete adjuvant according to a ratio of 1: 1: 1, injecting to the third pair of mammary glands of the mouse, and completing modeling in two weeks. The pathological characteristics of the model are highly matched with human diseases, the success rate is high, the repeatability is strong, and the model can be used for GM pathogenesis research and therapeutic drug screening.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

The present application relates to the technical field of biomedical materials, and particularly relates to porous hydroxyapatite particles, a preparation method and application thereof, which comprises the following steps: step S1, crosslinking a crosslinking agent and a macromolecular polymer to obtain a polymer gel; step S2, granulating the polymer gel to obtain gel particles; step S3, soaking the gel particles in a calcium ion solution, washing thoroughly, then soaking in a phosphate solution, washing thoroughly, repeating the foregoing operation for several times to mineralize, and obtaining mineralized gel particles; and step S4, calcining the mineralized gel particles in a muffle furnace at high temperature to obtain porous hydroxyapatite particles; the present application carries out biomimetic mineralization by using a polymer gel as a template, and the pore density can be determined according to the crosslinking degree of the polymer gel, so that the degradation environment can be effectively adapted to realize rapid and safe degradation, and no adverse reactions such as granuloma and hard nodules are caused.

Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.

The application discloses a granuloma circular representation positioning method and system based on multi-scale feature aggregation, first, collecting a histopathological image; then, performing preliminary feature encoding and extraction through a Patch Embedding module of a detection network; then, obtaining multi-scale aggregation feature output through a plurality of multi-scale attention feature extraction stages of the detection network; further, performing different scale feature fusion from top to bottom on the output features of each feature extraction stage through a feature fusion module FPN of the detection network; finally, positioning and detecting the granuloma in the histopathological image through three detection heads of the detection network; the application uses a Transformer structure based on multi-scale feature aggregation to extract image features, so that effective learning of a plurality of different scale features is realized, and the effect that both large targets and small targets can be effectively detected is achieved.

The invention relates to application of aspirin in preparation of an anti-schistosoma japonicum medicine, and in the invention, by applying a schistosoma japonicum infection mouse model, the treatment effect of aspirin on schistosoma japonicum is found. Specifically, the aspirin can significantly reduce the number of insect bodies infected in mice and the number of eggs deposited in livers, and can effectively inhibit the antigen secretion ability of the eggs infected in the livers of the mice, the granuloma inflammation induced by the eggs and the hepatic fibrosis degree, so that the aspirin can be applied to treatment of schistosoma japonicum katsurada. And a new application of aspirin is added clinically. As a non-steroidal anti-inflammatory drug, aspirin is widely applied clinically, has the advantages of safety, reliability, stability, low cost, easiness in obtaining and the like, and is relatively deep in pharmacological research and relatively clear in action mechanism. Therefore, the scheme of the invention is suitable for clinical popularization and use.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.

Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.

The application discloses a kind of external use traditional Chinese medicine preparation for treating cold blood stasis type granulomatous lobular mastitis and preparation method, and external use traditional Chinese medicine preparation is made of the raw materials including the following medicinal materials: prepared rhizome of rehmannia, antler slice, cassia, gunpowder ginger, chuanxiong, safflower, golden cypress, radix angelicae pubescentis, spironolactone, white and so on.The external preparation formula of the application is warm and blood tonic, blood-activating and skin-regenerating, has better clinical effect of treating cold blood stasis type granulomatous lobular mastitis, can effectively reduce the size of mass in clinical test, improve patient life treatment score, reduce the pain of patient, and has greater popularization and application value.

This invention relates to the field of pharmaceutical technology, and discloses the application of Ganoderma lucidum spore oil in the preparation of drugs for the prevention and treatment of pulmonary nodules. Animal model experiments have shown that Ganoderma lucidum spore oil has a significant inhibitory effect on the occurrence and development of benign granulomatous nodules in the lungs of mice, and at the same time has good safety. Therefore, it can be used to prepare drugs for the prevention and treatment of pulmonary nodules.

The present application provides siRNA delivery nanomaterials targeting M2 macrophages, which are mannosylated bovine serum albumin nanoparticles encapsulating siRNA interfering with KLK12. The mannose coating of the materials of the present application can provide targeting effect on M2 macrophages, and the siRNA released after endocytosis of the materials can silence the expression of KLK12 and its downstream MMPs genes, reduce the degradation of collagen fibers in lung tissues, thereby controlling the number and volume of pulmonary tuberculosis granulomas, preventing the occurrence of active tuberculosis, and providing a new option for the treatment of tuberculosis.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

The invention belongs to the technical field of biology, mainly relates to a preparation method of a composite adjuvant, and particularly relates to a water-soluble immune composite adjuvant, a vaccine and a preparation method of the vaccine. According to the compound adjuvant, every 300 mL of the compound adjuvant is prepared from 30 mL to 50 mL of carbomer stock solution, 30 mL to 37.5 mL of polyinosinic stock solution, 800 mg to 900 mg of triterpenoid saponin, 1.2 g of chitosan oligosaccharide and 20 mL of chitosan solution. Wherein the concentration of the carbomer stock solution is 30 mg / mL, the concentration of the polyinosinic-polycytidylic acid stock solution is 50 mg / mL, and the concentration of the chitosan solution is 600 mg / mL. The water-soluble immune composite adjuvant disclosed by the invention does not contain mineral oil components, granuloma of an injection part caused by viscous oil adjuvant vaccines is avoided, the water-soluble immune composite adjuvant is conveniently mixed with antigens in use, the economic benefits and the use convenience of farmers are effectively improved, and the water-soluble immune composite adjuvant is easy to industrially produce. And meanwhile, the gleditsia sinensis saponin enzymatic hydrolysate and the chitosan oligosaccharide enzymatic hydrolysate contained in the adjuvant have a synergistic effect, so that a relatively strong immune effect is achieved, humoral immune response and cellular immune response can be stimulated, and the immune persistence can be enhanced.

The utility model relates to the technical field of medical protection, and discloses an anti-infection isolation protective fence for granulocyte deficiency patients, which comprises a plurality of protective fences and a connecting structure, and the connecting structure is used for connecting the protective fences; the connecting structure comprises a first rotating seat and a second rotating seat which are fixedly connected to the two sides of the protective fence respectively, the first rotating seat is rotationally connected with a rotating shaft, the end of the rotating shaft is matched with the second rotating seat on other protective fences, and the second rotating seat rotates to drive the rotating shaft to rotate. According to the device, through hinged linkage matching of the multiple sets of rotating seats, the rotating shafts and the rotating plates and combination of a clamping block, a spring and a push plate connecting structure which can be conveniently locked and unlocked, angle-adjustable flexible rotation and stable fixation of the adjacent protective fences are achieved, the layout requirements of different installation spaces can be met, rapid assembly and disassembly are convenient, and the practicability is high. The universality and the operation convenience of the device are improved, the overall isolation function is guaranteed, and a convenient and flexible isolation chamber is provided for a patient suffering from particle deficiency with light illness.

The invention relates to the technical field of disease diagnosis, and provides a specific biomarker for granulomatous mastitis and a preparation method and application thereof, the specific biomarker is nicotinamide phosphoribosyltransferase truncated protein, and the amino acid sequence of the specific biomarker is shown as SEQ ID NO. 1. The NAMPT truncated protein is a specific molecule directly related to the GM pathogenesis. The detection result has high directivity, the positive result supports GM diagnosis, and the negative result is helpful for eliminating the GM diagnosis, so that non-iconography objective evidence is provided for differential diagnosis. GM and breast cancer are clearly distinguished in the early stage of diagnosis, and unnecessary anti-cancer treatment or delay of the real illness state is avoided.

The present disclosure relates to antigen binding compositions, including antibodies, and related methods for treating interleukin 5 (IL-5) mediated diseases. IL-5 is a secreted protein. IL-5 plays a role in a variety of different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis, and severe atopic dermatitis. The disclosed compositions are suitable for treating these severe IL-5 mediated diseases.

The present disclosure relates, in general, to the methods for the rapid detection of the presence or absence of Lymphogranuloma Venereum (LGV)-causing serovars of Chlamydia trachomatis in a biological or non-biological sample. The methods can include performing an amplification step, a hybridization step, and a detection step. Furthermore, oligonucleotide primers and probes targeting the pmpH gene for the L serovars of Chlamydia trachomatis, along with kits are provided that are designed for the detection of L serovars.

Provided herein are methods of treating eosinophilic polyvasculitis (EGPA), the methods comprising administering to a subject a therapeutically effective amount of an anti-interleukin-5 receptor alpha (IL-5R alpha) antibody, such as benralizumab, or an antigen-binding fragment thereof.

Described herein are compositions and methods for highly efficient and specific base-editing to correct two distinct X-linked chronic granulomatous disease (X-CGD) mutations, CYBB c.676C>T and c.1075G>A.